Renowned information technology and service provider to healthcare organizations,
Allscripts Healthcare Solutions, Inc. MDRX recently announced that its dbMotion Solution platform has been selected by South Western Sydney PHN (SWSPHN) to deliver integrated care. Notably, dbMotion Solution is Allscripts’ proprietary Community interoperability platform.
Coming back to the news, Allscripts’ dbMotion integrates discrete real-time patient data from diverse care settings and health information technology systems into a single patient record and provider workflow. Such synchronized information across the entire system enables providers to easily access and manage information within familiar workflows, facilitate better care and disease management.
SWSPHN is a not-for-profit health organization focused toward supporting general practitioners, practice nurses and other primary health providers. It aims to improve access to quality local health care for the whole community. It is the first Asia-Pacific organization to select the dbMotion Solution platform.
The dbMotion Solution will support SWSPHN’s overall goals of improving their clinical excellence and advancement of leading quality care. It would also help SWSPHN to collaborate with internationally recognized dbMotion sites located in the United States, Canada, U.K. and Israel.
Over the past three months, Allscripts has outperformed the broader
industry. The stock has increased 10.7% compared with only 0.9% gain of the industry it belongs to.
Allscripts is a leading provider of healthcare information technology solutions. Management is focused on various restructuring initiatives such as streamlining operational efficiency, increasing R&D and catering to client needs, going forward. We believe that favorable demographic trends, reinforced by a supportive regulatory environment, are expected to sustain growth in demand for its services.
Zacks Rank & Key Picks
Allscripts carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corporation (
EW Quick Quote EW - Free Report) , Lantheus Holdings, Inc. LNTH and IDEXX Laboratories, Inc. IDXX. Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 25.9% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 25.8% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 5.4% over the last six months.
4 Surprising Tech Stocks to Keep an Eye On Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off. See Stocks Now>>